The Yoplait Save Lids to Save Lives Tour with Adamari Lopez last week kicked off its 2012 breast-cancer awareness campaign in the Hispanic community. The tour will take the popular actress, television host and breast cancer survivor to eight U.S. cities with large Hispanic populations, where Ms. Lopez will continue to urge early breast cancer detection among Latinas and enlist their support for Yoplait’s Save Lids to Save Lives initiative.
Ms. Lopez’s tour kicked off Sept. 6 in Miami and ends Oct. 26 in Houston. She will also visit New York, Chicago, Los Angeles, Dallas, Houston, San Antonio and Phoenix, where she will take her message of hope to Latinas through media interviews and appearances at supermarkets. This is the fifth consecutive year that Yoplait and Ms. Lopez have teamed up on behalf of Save Lids to Save Lives®, which benefits Susan G. Komen for the Cure. For the past 14 years, Yoplait has been a passionate supporter of the fight against breast cancer, donating more than $34 million to the cause through all of its programs.
“I’m delighted once again to team up with Yoplait to help Latina women understand the importance of their breast health and inspire others to join the fight against the disease,” said Ms. Lopez, who emphasized that she was able to overcome her breast cancer diagnosis seven years ago thanks to early detection and “the tremendous support I received from my family.”
“My successful struggle with breast cancer is a testament to the fact that early detection can and does save lives, and that we are all in this together – mothers, daughters, wives, sisters, neighbors, best friends. These are the people who mean the most to us, and they are all at risk for breast cancer. To take care of the women in your life, you have to know more about breast health.”
Breast cancer is the most common form of cancer among Hispanic women. Compared to non-Hispanic White women, Latinas are less likely to have regular mammograms and follow-up for an abnormal mammogram* – a fact that may explain why they are more likely to be diagnosed at later stages of breast cancer, when the disease is more difficult to treat.**